RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $70
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $66 to $70.
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $66 to $70.